Comparative Pharmacology
Head-to-head clinical analysis: CROMOLYN SODIUM versus INTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOLYN SODIUM versus INTAL.
CROMOLYN SODIUM vs INTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Category A/B
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer